Carboxypeptidase B1 in dialyzed chronic kidney disease patients
Abstract Carboxypeptidase B1 has long been known to be a pancreas-specific tissue enzyme. In this paper we focus on Carboxypeptidase B1 concentration measurement in dialyzed chronic kidney kidney disease patients and on the effect dialysis adequacy and regimen exert on its concentration. A total of...
Saved in:
Main Authors: | Matej Stančík, Marián Grendár, Marián Mokáň |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-88332-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trimethylamine N-Oxide (TMAO) Plasma Levels in Patients with Different Stages of Chronic Kidney Disease
by: Marcia Ribeiro, et al.
Published: (2024-12-01) -
Microbial-Derived Uremic Toxins: Role in the Pathogenesis of Comorbidities in Patients with Chronic Kidney Disease
by: M. O. Pyatchenkov, et al.
Published: (2023-09-01) -
Metabolomics to Identify Unclassified Uremic Toxins: A Comprehensive Literature Review
by: Raymond Vanholder, et al.
Published: (2025-03-01) -
Alterations in gut‐derived uremic toxins before the onset of azotemic chronic kidney disease in cats
by: Laurens Van Mulders, et al.
Published: (2025-01-01) -
Protein-bound uremic toxins as therapeutic targets for cardiovascular, kidney, and metabolic disorders
by: Shihan Zhang, et al.
Published: (2025-01-01)